Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.
Avilar Therapeutics has raised $15.0M in total funding. The most recent round was Seed. The last funding was announced in February 2023.
Avilar Therapeutics's investors include RA Capital Management, Sanofi Ventures, Medical Excellence Capital, Astellas Venture Management.
Avilar Therapeutics is headquartered in Waltham, United States.
Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.
Avilar Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Avilar Therapeutics — Funding & Investors." VCBacked, February 16, 2023, https://www.vcbacked.co/company/avilar-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Avilar Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/avilar-therapeutics
{{cite web |title=Avilar Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/avilar-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated